Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Shanghai Junshi Biosciences Co's Net Current Asset Value or its related term are showing as below:
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shanghai Junshi Biosciences Co was 39.26. The lowest was 8.20. And the median was 14.30.
FRA:8SJ's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.84 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Shanghai Junshi Biosciences Co (FRA:8SJ) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shanghai Junshi Biosciences Co Net Current Asset Value Related Terms
Shanghai Junshi Biosciences Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co Net Current Asset Value Chart
FRA:8SJ vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-0.22 mean?
Shanghai Junshi Biosciences Co (FRA:8SJ) has a Net Current Asset Value of €-0.22 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai Junshi Biosciences Co and its competitors. Over the past decade, Shanghai Junshi Biosciences Co's Net Current Asset Value has ranged from 8.20 to 39.26. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 940 companies in the Biotechnology industry.
Is Shanghai Junshi Biosciences Co's Net Current Asset Value too high?
Shanghai Junshi Biosciences Co's current Net Current Asset Value is €-0.22. Over the past 10 years, this metric has ranged from a low of 8.20 to a high of 39.26. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #999999 out of 940 companies for Net Current Asset Value. This places Shanghai Junshi Biosciences Co in the lower half of its industry. The industry median Net Current Asset Value is 4.84. Historically, Shanghai Junshi Biosciences Co's own Net Current Asset Value has ranged from 8.20 to 39.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.84, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shanghai Junshi Biosciences Co and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current Net Current Asset Value is €-0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (FRA:8SJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.30, compared to a current price of €1.95 — trading 40.9% below its estimated fair value. The current Net Current Asset Value is €-0.22. Shanghai Junshi Biosciences Co's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (FRA:8SJ), the current Net Current Asset Value is €-0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (FRA:8SJ) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of €1.95 is trading 40.9% below its estimated GF Value™ of €3.30.
GuruFocus considers Shanghai Junshi Biosciences Co to be Significantly Undervalued.
Key valuation signals for FRA:8SJ:
Net Current Asset Value: €-0.22
GF Value™: €3.30 vs. price of €1.95 (40.9% below fair value)
No single metric tells the full story. See the FRA:8SJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
59GF Score
Get the complete analysis for FRA:8SJ
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8SJ has been successfully added to your 
